Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Poole

Showing results (611-620 of 623) with videos related to

Pageof 63
Sort By:
The New England Journal of Medicine|November 3, 2006
Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancerChristopher J Poole, Helena M Earl, Louise Hiller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2014
Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patientsH R Ali, E Provenzano, S-J Dawson, et al.
Human Vaccines & Immunotherapeutics|August 26, 2022
A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responsesGabriel I Nistor, Robert O Dillman, Rockelle M Robles, et al.
The Lancet. Oncology|December 28, 2020
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trialRobert D Morgan, Iain A McNeish, Adrian D Cook, et al.
Vox Sanguinis|March 14, 2007
International Society of Blood Transfusion Committee on Terminology for Red Cell Surface Antigens: Cape Town reportG Daniels, W A Flegel, A Fletcher, et al.
The Review of Scientific Instruments|March 5, 2008
Ion sources for energy extremes of ion implantationA Hershcovitch, B M Johnson, V A Batalin, et al.
Vox Sanguinis|January 21, 2009
International Society of Blood Transfusion Committee on terminology for red blood cell surface antigens: Macao reportG Daniels, L Castilho, W A Flegel, et al.
British Journal of Cancer|December 4, 1998
Chemotherapy for ovarian cancer--a consensus statement on standard practiceM Adams, A H Calvert, J Carmichael, et al.
The Lancet. Oncology|May 9, 2017
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Helen C Howard, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Pageof 63

Showing results (611-620 of 623) with videos related to

Sort By:
Pageof 63
The New England Journal of Medicine|November 3, 2006
Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancerChristopher J Poole, Helena M Earl, Louise Hiller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2014
Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patientsH R Ali, E Provenzano, S-J Dawson, et al.
Human Vaccines & Immunotherapeutics|August 26, 2022
A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responsesGabriel I Nistor, Robert O Dillman, Rockelle M Robles, et al.
The Lancet. Oncology|December 28, 2020
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trialRobert D Morgan, Iain A McNeish, Adrian D Cook, et al.
Vox Sanguinis|March 14, 2007
International Society of Blood Transfusion Committee on Terminology for Red Cell Surface Antigens: Cape Town reportG Daniels, W A Flegel, A Fletcher, et al.
The Review of Scientific Instruments|March 5, 2008
Ion sources for energy extremes of ion implantationA Hershcovitch, B M Johnson, V A Batalin, et al.
Vox Sanguinis|January 21, 2009
International Society of Blood Transfusion Committee on terminology for red blood cell surface antigens: Macao reportG Daniels, L Castilho, W A Flegel, et al.
British Journal of Cancer|December 4, 1998
Chemotherapy for ovarian cancer--a consensus statement on standard practiceM Adams, A H Calvert, J Carmichael, et al.
The Lancet. Oncology|May 9, 2017
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Helen C Howard, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Pageof 63